Dosing Septra DS for a 49 kg Child
For a 49 kg child, the appropriate dose of trimethoprim-sulfamethoxazole (Septra DS) depends on the indication, but for most common infections, give 8-12 mg/kg/day of the trimethoprim component divided into two doses every 12 hours, which translates to approximately 1-1.5 DS tablets twice daily.
Indication-Specific Dosing
For Skin and Soft Tissue Infections (SSTI)
For purulent cellulitis or MRSA coverage, administer 8-12 mg/kg/day based on the trimethoprim component in 2 divided doses 1. For a 49 kg child:
- Trimethoprim component: 392-588 mg/day total
- This equals approximately 1 DS tablet (160 mg TMP/800 mg SMX) twice daily for the lower end, or 1.5 DS tablets twice daily for higher dosing
- Duration: typically 5-10 days depending on clinical response
For Urinary Tract Infections or Acute Otitis Media
The FDA-approved dosing is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, divided every 12 hours for 10 days 2. For a 49 kg child:
- This calculates to 1 DS tablet twice daily (each DS tablet contains 160 mg TMP/800 mg SMX)
- Duration: 10 days for UTI, 5 days for shigellosis
For Pneumocystis Pneumonia (PCP)
Treatment dosing: 15-20 mg/kg/day of trimethoprim component (75-100 mg/kg/day of sulfamethoxazole) divided every 6 hours for 14-21 days 3, 2. For a 49 kg child:
- This equals 2-2.5 DS tablets every 6 hours (approximately 8-10 DS tablets per day total)
- This is substantially higher than prophylactic dosing
Prophylaxis dosing: 150 mg/m²/day trimethoprim with 750 mg/m²/day sulfamethoxazole, given in 2 divided doses, 3 consecutive days per week 4. The total daily dose should not exceed 320 mg trimethoprim and 1600 mg sulfamethoxazole (2 DS tablets) 2.
Important Clinical Considerations
Age-Related Pharmacokinetics
Children have higher clearance and shorter half-lives of TMP-SMX compared to adults 5. Research demonstrates that children aged 8-10 years have a mean elimination half-life of 5.4 hours versus 11.2 hours in adults, with higher total clearance (2.4 ml/min/kg vs 1.4 ml/min/kg) 5. This supports the need for weight-based dosing rather than simply using adult tablets.
Monitoring Requirements
- Complete blood counts should be performed at initiation and monthly intervals to assess for hematologic toxicity (neutropenia, thrombocytopenia, anemia) 6
- Monitor renal function, particularly with prolonged therapy
- Watch for hyperkalaemia, which occurs in 27.4% of patients on high-dose therapy 7
Common Pitfalls to Avoid
- Do not use in children under 2 months of age 2
- Septra DS tablets are "double strength" - each contains 160 mg TMP/800 mg SMX. Regular strength tablets contain 80 mg TMP/400 mg SMX. Ensure you're prescribing the correct formulation
- For severe infections requiring IV therapy, dosing differs significantly and should be calculated separately
- Adjust dosing in renal impairment: For creatinine clearance 15-30 mL/min, give half the usual dose; avoid use if CrCl <15 mL/min 2
Adverse Effects
The most common adverse reaction is rash, occurring at nearly 3-fold higher rates compared to other antibiotics 8. Serious reactions include Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), and hematologic abnormalities 3. If urticarial rash or Stevens-Johnson syndrome occurs, discontinue immediately and do not rechallenge 3.